January 09, 2025 11:52 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
6 dead in stampede near Tirupati temple during token distribution to offer prayers | Prominent journalist-film producer Pritish Nandy dies of cardiac arrest at 73 | Thousands, including Hollywood stars, flee Los Angeles upscale neighbourhood as wildfire engulfs homes | Sheesh Mahal row: AAP leaders who were denied entry into CM's residence turn towards PM's house | Anna University sexual assault accused is a DMK supporter, not member: MK Stalin | Ajit Doval, Raja Dato discuss bilateral cooperation during India-Malaysia Security Dialogue | US President-elect Donald Trump threatens to use economic force to make Canada 51st US State, Justin Trudeau retorts sharply | Elon Musk raises concern on 'world population decline' including that of India, China | Indian-origin Anita Ananda might replace Justin Trudeau as Canadian PM | 'I won't bite': Kamala Harris tells Senator's husband as he refuses to shake hands with her
WHO backs Regeneron COVID-19 drug cocktail - with equal access, price cut

WHO backs Regeneron COVID-19 drug cocktail - with equal access, price cut

Sep 25, 2021, at 04:29 pm

New York: The Regeneron antibody drug cocktail – casirivimab and imdevimab – has been added to the World Health Organization’s (WHO) list of treatments for COVID-19 patients, the UN agency said on Friday, before underscoring the need for lower prices and equitable distribution.

Sanofi and Regeneron announce FDA approval of Dupixent

Sanofi and Regeneron announce FDA approval of Dupixent

Mar 30, 2017, at 05:11 am

Mumbai/Kolkata, Mar 29 (IBNS): Sanofi and Regeneron Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved Dupixent (dupilumab) Injection, the first and only biologic medicine approved for the treatment of adults with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable.